出典: meddic


Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2012/06/11 11:50:06」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.


  • Pegvisomant and cabergoline combination therapy in acromegaly.
  • Bernabeu I, Alvarez-Escolá C, Paniagua AE, Lucas T, Pavón I, Cabezas-Agrícola JM, Casanueva FF, Marazuela M.SourceEndocrinology Department, Complejo Hospitalario Universitario de Santiago de Compostela (SERGAS), Travesía de la Choupana s/n, 15706, Santiago de Compostela, Spain,
  • Pituitary.Pituitary.2013 Mar;16(1):101-8. doi: 10.1007/s11102-012-0382-z.
  • Combination with cabergoline may offer additional benefits to acromegalic patients on pegvisomant monotherapy. We evaluated the safety and efficacy profile of this combination and investigated the determinants of response. An observational, retrospective, cross-sectional study. Fourteen acromegalic
  • PMID 22396133
  • Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patient.
  • Fendri S, Karaca P, Tiev E, Buchfelder M, Lalau JD.SourceService d'endocrinologie-nutrition, hôpital Sud, université Picardie-Jules-Verne, centre hospitalier universitaire, 80054 Amiens, France.
  • Annales d'endocrinologie.Ann Endocrinol (Paris).2013 Feb;74(1):49-52. doi: 10.1016/j.ando.2012.10.002. Epub 2013 Jan 18.
  • We report on a 30-year-old female acromegalic patient treated with the growth hormone (GH) receptor antagonist pegvisomant at a low dose after the failure of long-acting lanreotide, neurosurgery and radiotherapy treatment to restore IGF-1 levels. The combination treatment was well tolerated and prod
  • PMID 23337021
  • Optic neuropathy in McCune-Albright syndrome: effects of early diagnosis and treatment of growth hormone excess.
  • Boyce AM, Glover M, Kelly MH, Brillante BA, Butman JA, Fitzgibbon EJ, Brewer CC, Zalewski CK, Cutler Peck CM, Kim HJ, Collins MT.SourceSkeletal Clinical Studies Unit, Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health (NIH), Bethesda, Maryland 20892, USA.
  • The Journal of clinical endocrinology and metabolism.J Clin Endocrinol Metab.2013 Jan;98(1):E126-34. doi: 10.1210/jc.2012-2111. Epub 2012 Oct 23.
  • CONTEXT: GH excess is a serious complication of McCune-Albright syndrome (MAS) and has been associated with craniofacial morbidity.OBJECTIVE: The aim of the study was to determine whether early diagnosis and treatment of MAS-associated GH excess prevents optic neuropathy and hearing impairment, the
  • PMID 23093488


  • Poorly-controlled Acromegaly Accompanied by Subclinical Adrenal Cushing's Syndrome after Surgery for Multiple Endocrine Tumors
  • , , , , , , ,
  • Internal Medicine 54(6), 617-620, 2015
  • … Her GH and insulin-like growth factor-1 levels were insufficiently controlled, and pegvisomant was administered in addition to octreotide acetate. …
  • NAID 130004903084
  • 下垂体腺腫の最前線
  • 松野 彰
  • Neuro-Oncologyの進歩 21(1), 29-39, 2014
  • … Long-acting octreotide, lanreotide and pegvisomant are now available for growth hormone producing adenoma. …
  • NAID 130004648362
  • 下垂体腺腫に対する薬物療法 : 現状と課題
  • 富永 篤,木下 康之,碓井 智,栗栖 薫
  • 脳神経外科ジャーナル = Japanese journal of neurosurgery 22(2), 101-108, 2013-02-20
  • …  先端巨大症ではsomatostatin analogやpegvisomantなど有効率が高い薬剤があるが, 根治できないことが課題である. …
  • NAID 10031138807


SOMAVERT® (pegvisomant) is a prescription medicine for treating patients with acromegaly. Learn the risks and benefits of SOMAVERT®. ... Do not use SOMAVERT ® (pegvisomant for injection) if you are allergic to SOMAVERT ...
pegvisomant, a rarely used miscellaneous agent. indications This drug is used to treat acromegaly in those patients who have an inadequate response to other treatment. contraindications Latex allergy and known hypersensitivity to ...